Compare AbbVie Inc (ABBV) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? AbbVie Inc trades at $248.03 (market cap $441.94B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.72. The key difference: AbbVie Inc pays a 2.77% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | VNQI | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | — |
52-Week High | $263.58 | $50.76 |
52-Week Low | $197.38 | $43.26 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.82, up 0.57% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the US, featuring a higher dividend yield than domestic alternatives. Recent news highlights comparisons with US-focused REIT ETFs, emphasizing VNQI's global diversification benefits and competitive expense ratio.
The outlook remains positive given international real estate diversification and income appeal, though performance has lagged US counterparts. Key risks include currency fluctuations, geopolitical factors affecting foreign markets, and interest rate sensitivity. Institutional activity shows mixed signals with recent significant position reductions by some funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
